drugset / Trial / NCT05948813
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.
Timeline
- Start
- 2023-08-17
- Primary completion
- 2025-06-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Osimertinib | Small molecule | 80 mg | Oral |
| Subject | TY-9591 | Unknown | 160 mg | Oral |